Repligen (NASDAQ:RGEN) Stock Price Down 2.2% – Here’s Why

Repligen Co. (NASDAQ:RGEN)’s stock price was down 2.2% during trading on Wednesday . The stock traded as low as $141.13 and last traded at $141.82. Approximately 19,791 shares traded hands during trading, a decline of 97% from the average daily volume of 661,426 shares. The stock had previously closed at $144.98.

Analyst Upgrades and Downgrades

RGEN has been the topic of several analyst reports. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Finally, Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Down 4.7 %

The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock’s 50-day simple moving average is $146.74 and its 200-day simple moving average is $148.86. The firm has a market capitalization of $7.72 billion, a P/E ratio of 579.92, a P/E/G ratio of 4.05 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same period in the prior year, the firm earned $0.53 EPS. The company’s revenue was down 3.2% compared to the same quarter last year. As a group, research analysts predict that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

A number of large investors have recently added to or reduced their stakes in RGEN. Andra AP fonden purchased a new stake in shares of Repligen in the 2nd quarter worth about $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen in the 2nd quarter worth about $33,000. UMB Bank n.a. lifted its position in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Lazard Asset Management LLC lifted its position in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Rothschild Investment LLC purchased a new position in Repligen during the 2nd quarter valued at about $57,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.